Defeating stem cell tourism FOREWORD

被引：14

作者：

Mason, Chris ^{[1
]}

Manzotti, Elisa ^{[2
]}

机构：

[1] Univ London Univ Coll, Adv Ctr Biochem Engn, London WC1E 7JE, England

[2] Future Med Ltd, London N3 1QB, England

来源：

REGENERATIVE MEDICINE | 2010年 / 5卷 / 05期

关键词：

critical path; expanded access; off-label prescribing; regulation; stem cell tourism; REGENERATIVE MEDICINE; OFF-LABEL; APPROVAL PROCESS; TRANSLATION;

D O I：

10.2217/RME.10.74

中图分类号：

Q813 [细胞工程];

学科分类号：

100113 [医学细胞生物学];

摘要：

引用

页码：681 / 686

页数：6

共 33 条

[1]

Donor-Derived Brain Tumor Following Neural Stem Cell Transplantation in an Ataxia Telangiectasia Patient [J].

Amariglio, Ninette ;

Hirshberg, Abraham ;

Scheithauer, Bernd W. ;

Cohen, Yoram ;

Loewenthal, Ron ;

Trakhtenbrot, Luba ;

Paz, Nurit ;

Koren-Michowitz, Maya ;

Waldman, Dalia ;

Leider-Trejo, Leonor ;

Toren, Amos ;

Constantini, Shlomi ;

Rechavi, Gideon .

PLOS MEDICINE, 2009, 6 (02) :221-231

[2]

Targeting recovery: Priorities of the spinal cord-injured population [J].

Anderson, KD .

JOURNAL OF NEUROTRAUMA, 2004, 21 (10) :1371-1383

[3]

[Anonymous], 2010, NEW OXFORD AM DICT

[4]

[Anonymous], ACC INV DRUGS OUTS C

[5]

*CLOS LOOK STEM CE, ISSCR

[6]

The FDA's Critical Path Initiative: A Brief Introduction [J].

Coons, Stephen Joel .

CLINICAL THERAPEUTICS, 2009, 31 (11) :2572-2573

[7]

Gaps, tensions, and conflicts in the FDA approval process: Implications for clinical practice [J].

Deyo, RA .

JOURNAL OF THE AMERICAN BOARD OF FAMILY PRACTICE, 2004, 17 (02) :142-149

[8]

Editorial, 2009, CURR PROTOC STEM CEL

[9]

*FDA, CRIT PATH 2010 UPD

[10]

*FDA, FDA EXP ACC INV DRUG

← 1 2 3 4 →